FOLH1 and neutropenia: Results from a large retrospective study by Heck et al. in 100 patients receiving 317 cycles of 177Lu-PSMA I&T indicated lower rates, with grade ≥ 3 anemia, neutropenia and thrombocytopenia in 9%, 6% and 6%, respectively [9].